Table 3. AP Treatment at Screening for DREaM Subjects.
| DREaM SUBJECTS N = 96 | |
| Duration of prior AP exposure, n (%) | |
| <6 months | 48 (50) |
| 6–12 months | 16 (17) |
| >12 months | 23 (24) |
| Missing data, n (%) | 9 (9) |
| Current AP treatment at screening,a n (%) | |
| Risperidone | 25 (26) |
| Paliperidone | 18 (19) |
| Olanzapine | 12 (13) |
| Haloperidol | 8 (8) |
| Quetiapine | 8 (8) |
| Aripiprazole | 6 (6) |
| Lurasidone hydrochloride | 3 (3) |
| Other | 3 (3) |
| Loxapine | 1 (1) |
| Ziprasidone hydrochloride | 1 (1) |
| Not assignedb | 22 (23) |
Notes: aDrugs selected if they are used on the reference start date or 2 weeks before it.
bSubjects who were not assigned to any medications.